EUVIMEDEUVIMED entdecken
Crossref

Domain‐Specific Olfaction in Children and Adults in the Era of Modulator Therapy for Cystic Fibrosis

Jeremy P Tervo iD, Brandon M Moore iD, Emily DiMango, Hossein Sadeghi iD, Claire Keating, Daniel M Beswick, David A Gudis, Jonathan B Overdevest iD

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Jeremy P Tervo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head and Neck Surgery, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Olfaction Disorders, Smell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: This research was supported by the National Center for Advancing Translational Sciences (NCATS), the National Heart, Lung, and Blood Institute (NHLBI), and the…, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Little is known about when people with cystic fibrosis (PwCF) begin to experience olfactory decline, or whether sustained use of novel highly effective modulator therapies (HEMT) is predictive of better olfaction. This study evaluated psychophysical olfactory performance and HEMT‐associated olfactory outcomes in children and adults with CF.

Methods

In this cross‐sectional installment of a longitudinal study, individuals with a physician‐confirmed diagnosis of CF completed questionnaires and psychophysical olfactory assessment (i.e., standardized assessment of olfactory domains involving a battery of olfactory stimuli). HEMT consisted of either elexacaftor‐tezacaftor‐ivacaftor (ETI) or vezacaftor‐tezacaftor‐deuivacaftor (VTD). Analysis compared performance between pediatric versus adult cohorts and assessed the impact of HEMT on psychophysical olfactory performance while controlling for age, sex, genotype, and history of sinus surgery.

Results

Individuals < 21 years old had better psychophysical olfactory performance than those ≥ 21 years old (61% vs. 24% normosmia). Younger age at the start of HEMT was not associated with lowered odds of threshold hyposmia [OR: 0.73; 95% CI: (0.34, 1.50)] or identification hyposmia [OR: 0.67; 95% CI: (0.35, 1.22)] within this cohort.

Conclusion

Younger people with CF appear to have relatively preserved psychophysical olfactory function that appears to prematurely decline through early adulthood compared to the general population. Although younger age at the start of HEMT therapy was not associated with better olfactory outcomes, future prospective longitudinal studies could evaluate individuals′ olfaction across their lifespan to assess the full impact of HEMT on olfaction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisOlfaction DisordersSmellHumansMaleFemaleChildAdultAminophenolsCross-Sectional StudiesYoung AdultAdolescentQuinolonesLongitudinal StudiesBenzodioxolesIndolesCyclopropanesAge FactorsPyrroles

Stichwörter der Autor:innen

cystic fibrosislifespanmodulator therapyolfactionquality of lifesmell

Substanzen

AminophenolsQuinolonesBenzodioxolesivacaftortezacaftorIndolesCyclopropanesPyrroles

Autor:innen und Institutionen

  • Department of Otolaryngology - Head and Neck Surgery, Columbia University Irving Medical Center, New York, New York, USA.
  • Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
  • Department of Pulmonology, Columbia University Irving Medical Center, New York, New York, USA.
  • Department of Pediatric Pulmonology, Columbia University Irving Medical Center, New York, New York, USA.
  • Department of Otolaryngology-Head and Neck Surgery, University of California, Los Angeles, California, USA.

ORCID-Profile: Jeremy P Tervo, Brandon M Moore, Hossein Sadeghi, Jonathan B Overdevest

Förderung

  • This research was supported by the National Center for Advancing Translational Sciences (NCATS), the National Heart, Lung, and Blood Institute (NHLBI), and the…
  • National Center for Advancing Translational Sciences

Zitieren

APA

Tervo, J. P., Moore, B. M., DiMango, E., Sadeghi, H., Keating, C., Beswick, D. M., Gudis, D. A., & Overdevest, J. B. (2025). Domain‐Specific Olfaction in Children and Adults in the Era of Modulator Therapy for Cystic Fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71348

Vancouver

Tervo JP, Moore BM, DiMango E, Sadeghi H, Keating C, Beswick DM, et al. Domain‐Specific Olfaction in Children and Adults in the Era of Modulator Therapy for Cystic Fibrosis. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71348

BibTeX
@article{Tervo2025,
  author = {Tervo, Jeremy P and Moore, Brandon M and DiMango, Emily and Sadeghi, Hossein and Keating, Claire and Beswick, Daniel M and Gudis, David A and Overdevest, Jonathan B},
  title = {Domain‐Specific Olfaction in Children and Adults in the Era of Modulator Therapy for Cystic Fibrosis},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71348}
}
Kostenlos starten →